FDA — authorised 22 October 2021
- Application: BLA761197
- Marketing authorisation holder: GENENTECH INC
- Local brand name: SUSVIMO
- Indication: SOLUTION — INJECTION
- Status: approved
🇺🇸 RFB002 in United States
FDA authorised RFB002 on 22 October 2021
Marketing authorisations
FDA
- Status: approved
RFB002 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Other approved in United States
Frequently asked questions
Is RFB002 approved in United States?
Yes. FDA authorised it on 22 October 2021; FDA has authorised it.
Who is the marketing authorisation holder for RFB002 in United States?
GENENTECH INC holds the US marketing authorisation.